Roche cancer immunotherapy fails in late-stage trials; new opioid crisis settlement

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: CVS, Teva, and Allergan reach deal with Florida over the opioid crisis By Ed Silverman ERIC BARADAT/AFP via Getty Images The agreement between Florida and CVS, Teva, and Allergan is the latest in a growing number of settlements over the opioid crisis. Read More STAT+: Pharma companies face shareholder proposals to widen access to medicines, rework business plans By Ed Silverman Adobe Several major pharmaceutical companies will face new shareholder proposals that would require them to widen access to their medicines. Read More STAT+: Tracking the FDA advisory panel on Amylyx Pharma's ALS treatment By Adam Feuerstein and Nicholas Florko Sarah Silbiger/Getty Images Tune in for updates from a meeting where FDA advisers are reviewing data on the drug and will recommend whether or not it should be approved. Read More Sponsor content by STAT Events Last Chance: The STAT Breakthrough Science Summit This Thursday, leaders from Pfizer, Bristol Myers Squibb, and Merck will take the stage to discuss what’s next for their organizations. We’ll also explore the future of CRISPR and unpack the feasibility of pig-to-human transplants. There’s so much more, so check out statnews.com/summit to see the full agenda and find more information about our featured speakers. Then, get your ticket to join us! STAT+: Pharma partnerships with digital therapeutics players to watch  By Mario Aguilar INA FASSBENDER/AFP via Getty Images Pharma companies have struck a string of new deals with digital health startups. Here's STAT's guide to the partnerships to watch. Read More STAT+: Roche anti-TIGIT cancer immunotherapy fails in first late-stage clinical trial By Adam Feuerstein SEBASTIEN BOZON/AFP via Getty Images The result is the first from a group of late-stage clinical trials that Roche is conducting for its anti-TIGIT drug called tiragolumab. Read More Wednesday, March 30, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser